Aeon Biopharma, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
AMEX
AEON Biopharma, Inc. files an S-1MEF to increase its public offering size by $4,528,125, including over-allotment options.
AMEX
AEON Biopharma, Inc. has filed an amendment to its S-1 registration statement, primarily to update the filing fee table related to its proposed stock offering.
AMEX
AEON Biopharma, Inc. has filed a registration statement for a proposed offering of Class A common stock, pre-funded warrants, and milestone warrants.
AMEX
AEON Biopharma shifts strategy to pursue a biosimilar pathway for ABP-450, aiming for FDA approval across multiple therapeutic indications and registering securities for potential resale.
AMEX
AEON Biopharma is seeking to register the resale of a substantial number of its common stock and warrants, as well as shares issuable upon exercise of existing warrants and options.
AMEX
AEON Biopharma files for a potential $357 million resale of common stock and warrants, while also eyeing potential capital from warrant exercises.